ACAT2 and Hypercholesterolemia: Thus, as the Acat2 level in liver is decreased during HFD-induced obesity, our results suggest that liver-targeted adenoviral Acat2 overexpression represents a potential therapeutic strategy for obesity and its associated hypercholesterolaemia.